XML 34 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2020
Reconciliation of Numerators and Denominators used in Computing Basic and Diluted Net Income Per Share
The following is a reconciliation of the numerators and denominators used in computing basic and diluted net income per share:
 
   
Three Months Ended
  
Nine Months Ended
 
   
September 30,
2020
  
September 30,
2019
  
September 30,
2020
  
September 30,
2019
 
Net income (loss)
  $(5,448,046 $(4,229,833 $(12,444,644 $(8,172,000
  
 
 
  
 
 
  
 
 
  
 
 
 
Numerator, basic and diluted net income (loss) available to stockholders
  $(5,448,046 $(4,229,833 $(12,444,644 $(8,172,000
  
 
 
  
 
 
  
 
 
  
 
 
 
Denominator:
     
Shares used in computation – basic:
     
Weighted average common shares outstanding
   10,616,080   9,456,300   9,894,707   9,301,796 
  
 
 
  
 
 
  
 
 
  
 
 
 
 
   
Three Months Ended
  
Nine Months Ended
 
   
September 30,
2020
  
September 30,
2019
  
September 30,
2020
  
September 30,
2019
 
Common shares outstanding for basic
   10,616,080    9,456,300    9,894,707    9,301,796 
   
 
 
   
 
 
   
 
 
   
 
 
 
Shares used in computation – diluted:
     
Common shares outstanding for basic
   10,616,080   9,456,300   9,894,707   9,301,796 
  
 
 
  
 
 
  
 
 
  
 
 
 
Shares used in computing diluted net income per share
   10,616,080   9,456,300   9,894,707   9,301,796 
  
 
 
  
 
 
  
 
 
  
 
 
 
Net (loss) per share – basi
c
  $(0.51 $(0.45 $(1.26 $(0.88
Net (loss) per share – diluted
  $(0.51 $(0.45 $(1.26 $(0.88
Schedule of Financial Instruments at Fair Value on a Recurring Basis
We measure certain financial instruments at fair value on a recurring basis. The Company had liabilities that are required to be measured at fair value on a recurring basis as follows at
September
 30, 2020:
 
 
  
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
Assets:
  
$
—  
 
  
$
—  
 
  
$
—  
 
  
$
—  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
Liabilities:
  
   
  
   
  
   
  
   
Hybrid debt instrument at fair value
  
$
960,800
 
  
$
—  
 
  
$
—  
 
  
$
960,800
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
Reconciliation of the Beginning and Ending Balances for the Liability Measured at Fair Value on a Recurring Basis
The following is a reconciliation of the beginning and ending balances for the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2020: See NOTE I: Note 10 – 37North for further detail.
 
Balance at December 31, 2019
  $861,485 
Additional debt issuance
s
   490,000 
Conversion
   (1,066,219
Loss in hybrid-instrument fair value
   675,534 
  
 
 
 
Balance at
September
 30, 202
0
  $960,800 
  
 
 
 
In the Money Potential Common Shares [Member]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The potential common shares in the following tables represent potential common shares calculated using the
if-converted
method from outstanding options, stock awards and warrants that were excluded from the calculation of diluted EPS:
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,

2020
   
September 30,

2019
   
September 30,

2020
   
September 30,

2019
 
Average market price during the period  $5.25   $4.75   $4.45   $5.35 
In the money potential common shares from options excluded   22,493    9,449    22,493    10,984 
In the money potential common shares from warrants excluded   2,449,852    30,507    671,378    41,046 
Out of Money Potential Common Shares [Member]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potential common shares from out of the money options and warrants were also excluded from the computation of diluted EPS because calculation of the associated potential common shares has an anti-dilutive effect on EPS. The following table lists options and warrants that were excluded from diluted EPS:
 
 
  
Three Months Ended
 
  
Nine-Months Ended
 
Per share
exercise price
  
September 30,
2020
 
  
September 30,
2019
 
  
September 30,
2020
 
  
September 30,
2019
 
Out
 
of
 
the
 
money 
options
 excluded:
  
   
  
   
  
   
  
   
$12.48
   136,833   136,833   136,833   136,833
$12.84
   4,167    4,167    4,167    4,167 
$26.40
   75,158    75,158    75,158    75,158 
Out-of-the-money
warrants excluded:
 
      
$4.67
   —      —      131,816    —   
$4.75
   —      —      1,646,658    —   
$5.76
   196,135   —      196,135   —   
$7.16
   700,000   700,000   700,000   700,000
$12.00
       65,625       65,625
  
 
 
   
 
 
   
 
 
   
 
 
 
Total excluded   1,112,293    981,783    2,890,767    981,783 
  
 
 
   
 
 
   
 
 
   
 
 
 
Unvested Restricted Stock Awards Excluded from EPS [Member]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The common shares relating to our unvested restricted stock awards that were excluded from potential common shares in the earning per share calculation due to having an anti-dilutive effect are:
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 30,
2020
   
September 30,
2019
   
September 30,
2020
   
September 30,
2019
 
Potential common shares from unvested restricted stock awards excluded from EPS   343,353    41,667    343,353    41,667